This gene sequencing panel includes both sequencing and deletion/duplication (CNV) analysis for all coding regions of the included genes (unless otherwise noted). All analysis is performed utilizing next-generation sequencing (NGS) technology. All variants are classified according to American College of Genetics and Genomics (ACMG) guidelines.

This comprehensive panel includes genes associated with the following hereditary cancers and cancer syndromes:

• Bloom Syndrome
• Breast Cancer
• Carney Complex
• Costello Syndrome
• DICER1 Tumor Predisposition Syndrome
• Familial Meningioma
• Gastrointestinal and Colorectal Cancers
• Gynecological Cancers
• Hereditary Breast and Ovarian Cancer Syndrome
• Hereditary Thrombocytopenia and Hematologic Cancer Predisposition Syndrome
• Hyperparathyroidism with Jaw Tumor Syndrome
• Leukemia
• Li-Fraumeni Syndrome
• Lynch Syndrome
• Melanoma
• Mismatch Repair Cancer Syndrome
• Multiple Endocrine Neoplasia 
• Myelodysplastic Syndrome
• Neuroblastoma
• Neurofibromatosis
• Nevoid Basal Cell Carcinoma Syndrome
• Nijmegen Breakage Syndrome
• Non-Small Cell Lung Cancer
• NTHL1-Deficiency Tumor Predisposition Syndrome
• Pancreatic Cancer
• Paraganglioma
• Perlman Syndrome
• Peutz-Jeghers Syndrome
• Pheochromocytoma
• Pleuropulmonary Blastoma
• POT1 Tumor Predisposition Syndrome
• Prostate Cancer
• PTEN Hamartoma Tumor Syndrome
• Renal Cancer
• Retinoblastoma
• Rhabdoid Tumor Predisposition Syndrome
• Rothmund-Thomson Syndrome
• Tuberous Sclerosis
• Von Hippel-Lindau Syndrome
• Werner Syndrome
• Wilms Tumor

Please see professional society guidelines, including the National Comprehensive Cancer Network (NCCN), for the most up-to-date testing criteria.

AIP, ALK, ANKRD26, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDC73, CDH1, CDK4, CDKN1B, CDKN1C, CDKN2A, CEBPA, CHEK2, DDX41, DICER1, DIS3L2, EGFR, EPCAM, ETV6, EXT1, EXT2, EZH2, FANCC, FH, FLCN, GATA2, GPC3, GREM1, HOXB13, HRAS, KIT, LZTR1, MAX, MEN1, MET, MITF, MLH1, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51C, RAD51D, RB1 RECQL4, RET, RNF43, RUNX1, SAMD9, SAMD9L, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, SRP72, STK11, SUFU, TERC, TERT, TMEM127, TP53, TSC1, TSC2, VHL, WRN, WT1

Sequencing is performed on genomic DNA using an Agilent targeted sequence capture method to enrich for the exome. Direct sequencing of the amplified captured regions was performed using 2X150bp reads on Illumina next generation sequencing (NGS) systems. A base is considered to have sufficient coverage at 20X and an exon is considered fully covered if all coding bases plus three nucleotides of flanking sequence on either side are covered at 20X or more. A list of these regions, if any, is available upon request. Alignment to the human reference genome (GRCh37) is performed and annotated variants are identified in the targeted region. Variants reviewed have a minimum coverage of 8X and an alternate allele frequency of 20% or higher. Indel and single nucleotide variants (SNVs) may be confirmed by Sanger sequence analysis before reporting at director discretion. This assay cannot detect variants in regions of the exome that are not covered, such as deep intronic, promoter and enhancer regions, areas containing large numbers of tandem repeats, and variants in mitochondrial DNA. Copy number variation (CNV) analysis detects deletions and duplications; in some instances, due to the size of the exons, sequence complexity, or other factors, not all CNVs may be analyzed or may be difficult to detect. When reported, copy number variant size is approximate. Actual breakpoint locations may lie outside of the targeted regions. CNV analysis will not detect tandem repeats, balanced alterations (reciprocal translocations, Robertsonian translocations, inversions, and balanced insertions), methylation abnormalities, triploidy, and genomic imbalances in segmentally duplicated regions. This assay is not designed to detect mosaicism; possible cases of mosaicism may be investigated at the discretion of the laboratory director. Primary data analysis is performed using Illumina bcl2fastq converter v2.19. Secondary analysis is performed using Illumina DRAGEN Bio-IT Platform v.3.10.8. Tertiary data analysis is performed using SnpEff v5.0 and Revvity Omics’ internal ODIN v.1.01 software. CNV and absence of heterozygosity are assessed using BioDiscovery’s NxClinical v6.1 software.